Table 1
Demographic details of patients undergoing intravenous to subcutaneous infliximab switch
Number (%)
Total patients
75 (100)
Male
44 (58.7)
Female
31 (41.3)
Crohn’s disease
61 (81.3)
Ulcerative colitis
14 (18.7)
Median age
37